J&J says FTC probing efforts to protect arthritis drug Remicade

 J&J says FTC probing efforts to protect arthritis drug Remicade

WASHINGTON (Reuters) - The Federal Trade Commission in June issued civil subpoenas to Johnson and Johnson as part of an investigation of whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.

Shares of the company were trading marginally down at $132.47, after having closed up 1.7% on Monday.

(Reporting by Diane Bartz; Editing by Shinjini Ganguli)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date: Jul 30, 2019 03:05:51 IST